CRISPR Therapeutics AG (NASDAQ:CRSP) Position Decreased by Integral Health Asset Management LLC

Integral Health Asset Management LLC decreased its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 31.8% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 150,000 shares of the company’s stock after selling 70,000 shares during the period. Integral Health Asset Management LLC owned approximately 0.18% of CRISPR Therapeutics worth $8,102,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in the business. EverSource Wealth Advisors LLC boosted its position in shares of CRISPR Therapeutics by 38.1% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,572 shares of the company’s stock valued at $147,000 after purchasing an additional 710 shares in the last quarter. Itau Unibanco Holding S.A. bought a new position in shares of CRISPR Therapeutics during the 2nd quarter valued at about $35,000. Profund Advisors LLC boosted its position in shares of CRISPR Therapeutics by 84.2% during the 2nd quarter. Profund Advisors LLC now owns 32,416 shares of the company’s stock valued at $1,751,000 after purchasing an additional 14,820 shares in the last quarter. Westwood Holdings Group Inc. boosted its position in shares of CRISPR Therapeutics by 151.5% during the 2nd quarter. Westwood Holdings Group Inc. now owns 37,375 shares of the company’s stock valued at $2,019,000 after purchasing an additional 22,516 shares in the last quarter. Finally, Thrivent Financial for Lutherans boosted its position in shares of CRISPR Therapeutics by 51.5% during the 2nd quarter. Thrivent Financial for Lutherans now owns 47,223 shares of the company’s stock valued at $2,551,000 after purchasing an additional 16,051 shares in the last quarter. Institutional investors own 69.20% of the company’s stock.

Analysts Set New Price Targets

CRSP has been the subject of several recent analyst reports. Needham & Company LLC decreased their target price on shares of CRISPR Therapeutics from $88.00 to $84.00 and set a “buy” rating for the company in a report on Tuesday, August 6th. Barclays decreased their target price on shares of CRISPR Therapeutics from $67.00 to $59.00 and set an “equal weight” rating for the company in a report on Tuesday, August 6th. Piper Sandler reiterated an “overweight” rating and issued a $105.00 target price on shares of CRISPR Therapeutics in a report on Monday, June 17th. StockNews.com upgraded shares of CRISPR Therapeutics to a “sell” rating in a report on Friday, August 16th. Finally, Chardan Capital decreased their target price on shares of CRISPR Therapeutics from $112.00 to $94.00 and set a “buy” rating for the company in a report on Tuesday, August 6th. Three investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $75.63.

CRISPR Therapeutics Stock Performance

Shares of CRSP opened at $48.18 on Monday. The firm has a market cap of $4.09 billion, a PE ratio of -17.71 and a beta of 1.68. The firm’s 50 day moving average price is $50.45 and its 200 day moving average price is $56.83. CRISPR Therapeutics AG has a twelve month low of $37.55 and a twelve month high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Monday, August 5th. The company reported ($1.49) earnings per share for the quarter, missing the consensus estimate of ($1.43) by ($0.06). The company had revenue of $0.52 million for the quarter, compared to analysts’ expectations of $12.31 million. During the same quarter in the previous year, the firm posted ($0.98) earnings per share. The business’s quarterly revenue was down 99.3% on a year-over-year basis. On average, sell-side analysts anticipate that CRISPR Therapeutics AG will post -5.6 earnings per share for the current fiscal year.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.